Targeted News Service

Day 2 Highlights From the 20th International Myeloma Society Annual Meeting
October 02, 2023

NORWALK, Connecticut, Oct. 2 (TNSres) -- The Multiple Myeloma Research Foundation issued the following news:

Day 2 of IMS brought us some recent findings covering a mix of different drug combinations for both newly diagnosed and relapsed/refractory myeloma. Let's dig into a big day of updates in myeloma treatment.

Pomalidomide, Velcade, Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Revlimid is a key drug in the treatment of newl . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form